vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是STEM, INC.的1.6倍（$75.5M vs $47.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -15.6%），过去两年STEM, INC.的营收复合增速更高（36.1% vs 31.3%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
PBYI vs STEM — 直观对比
营收规模更大
PBYI
是对方的1.6倍
$47.1M
营收增速更快
PBYI
高出43.3%
-15.6%
两年增速更快
STEM
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $47.1M |
| 净利润 | — | $-16.0M |
| 毛利率 | 69.3% | 48.9% |
| 营业利润率 | 22.7% | -17.7% |
| 净利率 | — | -33.9% |
| 营收同比 | 27.7% | -15.6% |
| 净利润同比 | — | 68.8% |
| 每股收益（稀释后） | $0.26 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISTEM
| Q4 25 | $75.5M | $47.1M | ||
| Q3 25 | $54.5M | $38.2M | ||
| Q2 25 | $52.4M | $38.4M | ||
| Q1 25 | $46.0M | $32.5M | ||
| Q4 24 | $59.1M | $55.8M | ||
| Q3 24 | $80.5M | $29.3M | ||
| Q2 24 | $47.1M | $34.0M | ||
| Q1 24 | $43.8M | $25.5M |
净利润PBYISTEM
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $8.8M | $-23.8M | ||
| Q2 25 | $5.9M | $202.5M | ||
| Q1 25 | $3.0M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $20.3M | $-148.3M | ||
| Q2 24 | $-4.5M | $-582.3M | ||
| Q1 24 | $-4.8M | $-72.3M |
毛利率PBYISTEM
| Q4 25 | 69.3% | 48.9% | ||
| Q3 25 | 77.7% | 35.5% | ||
| Q2 25 | 76.5% | 33.4% | ||
| Q1 25 | 77.1% | 32.4% | ||
| Q4 24 | 76.4% | -4.4% | ||
| Q3 24 | 63.9% | 21.2% | ||
| Q2 24 | 77.4% | 27.6% | ||
| Q1 24 | 75.5% | -95.0% |
营业利润率PBYISTEM
| Q4 25 | 22.7% | -17.7% | ||
| Q3 25 | 17.6% | -33.6% | ||
| Q2 25 | 12.7% | -34.8% | ||
| Q1 25 | 8.7% | -65.0% | ||
| Q4 24 | 22.6% | -84.4% | ||
| Q3 24 | 27.4% | -493.2% | ||
| Q2 24 | -4.6% | -1705.5% | ||
| Q1 24 | -5.3% | -267.0% |
净利率PBYISTEM
| Q4 25 | — | -33.9% | ||
| Q3 25 | 16.2% | -62.2% | ||
| Q2 25 | 11.2% | 527.8% | ||
| Q1 25 | 6.5% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | 25.2% | -506.3% | ||
| Q2 24 | -9.6% | -1712.6% | ||
| Q1 24 | -11.0% | -283.9% |
每股收益（稀释后）PBYISTEM
| Q4 25 | $0.26 | $-4.40 | ||
| Q3 25 | $0.17 | $-2.84 | ||
| Q2 25 | $0.12 | $-1.79 | ||
| Q1 25 | $0.06 | $-0.15 | ||
| Q4 24 | $0.40 | $-15.29 | ||
| Q3 24 | $0.41 | $-18.24 | ||
| Q2 24 | $-0.09 | $-71.81 | ||
| Q1 24 | $-0.10 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $48.9M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $-249.4M |
| 总资产 | $216.3M | $308.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYISTEM
| Q4 25 | $97.5M | $48.9M | ||
| Q3 25 | $94.4M | $43.1M | ||
| Q2 25 | $96.0M | $40.8M | ||
| Q1 25 | $93.2M | $58.6M | ||
| Q4 24 | $101.0M | $56.3M | ||
| Q3 24 | $96.7M | $75.4M | ||
| Q2 24 | $96.8M | $89.6M | ||
| Q1 24 | $107.2M | $112.8M |
总债务PBYISTEM
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYISTEM
| Q4 25 | $130.3M | $-249.4M | ||
| Q3 25 | $115.3M | $-235.7M | ||
| Q2 25 | $104.7M | $-214.1M | ||
| Q1 25 | $97.1M | $-417.5M | ||
| Q4 24 | $92.1M | $-398.4M | ||
| Q3 24 | $71.1M | $-344.1M | ||
| Q2 24 | $48.5M | $-203.2M | ||
| Q1 24 | $51.0M | $371.6M |
总资产PBYISTEM
| Q4 25 | $216.3M | $308.9M | ||
| Q3 25 | $202.9M | $362.6M | ||
| Q2 25 | $194.9M | $379.2M | ||
| Q1 25 | $196.2M | $405.1M | ||
| Q4 24 | $213.3M | $437.4M | ||
| Q3 24 | $220.7M | $537.8M | ||
| Q2 24 | $205.0M | $691.5M | ||
| Q1 24 | $214.1M | $1.3B |
负债/权益比PBYISTEM
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYISTEM
| Q4 25 | $14.4M | $8.2M | ||
| Q3 25 | $9.7M | $11.4M | ||
| Q2 25 | $14.1M | $-21.3M | ||
| Q1 25 | $3.6M | $8.5M | ||
| Q4 24 | $15.6M | $-14.7M | ||
| Q3 24 | $11.0M | $-9.4M | ||
| Q2 24 | $1.0M | $-11.9M | ||
| Q1 24 | $11.2M | $-621.0K |
自由现金流PBYISTEM
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYISTEM
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYISTEM
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYISTEM
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | -0.11× | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
